RE:We need some confidence and action!Ron,
A few comments. From the information available, it seems the Phase III BETonMACE will begin enrollment in Fall 2015 regardless of the FDA (mutliple sources from RVX state this: MD&D, Annual Information Form, RVX website). If FDA approval is still pending, this would obviously mean that the patient population would initially be drawn from Europe and China. However, FDA approval may already be granted. RVX IR has stated multiple times that details of the trial will be disclosed at the time of official trial announcment/launch of trial. Even if FDA approval is not granted at the time of BETonMACE launch, this does not necessarily close the door for future FDA/US involvement in BETonMACE. Fall 2015......not too far away. Some say Fall starts in September........It sure would be timely if at the August 30th - September 2 ESC Congress in London, or at the September 14-18 EASD meeting in Sweden if they made a trial announcement. Since Europe is going to be a key player in the patient population, this would make sense.
Also, RVX stated in their Annual Information form that they have publications in the works for the SUSTAIN trial and Diabetes trial. So we may see some added exposure soon from peer reviewed science publications.
Lastley, Don has stated that he hopes to announce the new orphan indication prior to the September 30th Annual Meeting.
So there is definitely a chance for things on the horizon prior to the September 30th meeting!
And if you haven't already, check out Resverlogix's revamped website, including but not limited to the page on RVX/Apabetalone and the BETonMACE trial enrolling Fall 2015!
https://www.resverlogix.com/programs/rvx-208-clinical-development/
Best,
BDAZ